Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
暂无分享,去创建一个
W. Oyen | O. Hoekstra | E. D. de Vries | P. Flamen | L. Ameye | A. Awada | A. Awada | S. Stroobants | J. Tol | A. Brouwers | D. Vugts | C. Schröder | C. W. Menke-van der Houven van Oordt | L. E. Lamberts | M. Huizing | S. Stroobants | G. Gebhart | P. Aftimos | P. Emonts | E. D. Vries | T. Guiot | C. García | Z. Wimana | C. Schröder | P. Flamen | Oordt | C. Garcia | Catharina W. Menke-van der Houven van | Patrick Emonts